60
Participants
Start Date
August 31, 2009
Primary Completion Date
October 31, 2011
Study Completion Date
June 30, 2015
AMG 386
Two doses of AMG 386 (15 mg/kg) IV QW will be studied
AMG 386
Two doses of AMG 386 (10 mg/kg) IV QW will be studied
Sorafenib
Sorafenib 400 mg PO BID orally twice daily in an every 4 week dosing schedule for 15mg/kg cohort \& 10mg/kg cohort
Lead Sponsor
Amgen
INDUSTRY